l-NAME (Nω-Nitro-l-Arginine Methyl Ester), a Nitric-Oxide Synthase Inhibitor, and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6 H-pyrrolo[3,2,1 ij]quinolin-6-one], a Cannabinoid Agonist, Interact to Evoke Synergistic Hypothermia
- 1 February 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 308 (2) , 780-786
- https://doi.org/10.1124/jpet.103.054668
Abstract
Cannabinoids evoke profound hypothermia in rats by activating central CB1 receptors. Nitric oxide (NO), a prominent second messenger in central and peripheral neurons, also plays a crucial role in thermoregulation, with previous studies suggesting pyretic and antipyretic functions. Dense nitric-oxide synthase (NOS) staining and CB1 receptor immunoreactivity have been detected in regions of the hypothalamus that regulate body temperature, suggesting that intimate NO-cannabinoid associations may exist in the central nervous system. The present study investigated the effect of Nω-nitro-l-arginine methyl ester (l-NAME), a NO synthase inhibitor, on the hypothermic response to WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenylcarbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one], a selective cannabinoid agonist, in rats. WIN 55212-2 (1–5 mg/kg, i.m.) produced dose-dependent hypothermia that peaked 45 to 90 min post-injection. l-NAME (10–100 mg/kg, i.m.) by itself did not significantly alter body temperature. However, a nonhypothermic dose of l-NAME (50 mg/kg) potentiated the hypothermia caused by WIN 55212-2 (0.5–5 mg/kg). The augmentation was strongly synergistic, indicated by a 2.5-fold increase in the relative potency of WIN 55212-2. The inactive enantiomer of WIN 55212-2, WIN 55212-3 [S-(–)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-napthanlenyl) methanone mesylate] (5 mg/kg, i.m.), did not produce hypothermia in the absence or presence of l-NAME (50 mg/kg), confirming that cannabinoid receptors mediated the synergy. The present data are the first evidence that drug combinations of NOS blockers and cannabinoid agonists produce synergistic hypothermia. Thus, NO and cannabinoid systems may interact to induce superadditive hypothermia.This publication has 45 references indexed in Scilit:
- Role of the Nitric Oxide Pathway in κ-Opioid-Induced Hypothermia in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Differential role of the nitric oxide pathway on Δ9-THC-induced central nervous system effects in the mouseEuropean Journal of Neuroscience, 2001
- Production and physiological actions of anandamide in the vasculature of the rat kidney.Journal of Clinical Investigation, 1997
- Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in LeukocytesJournal of Biological Chemistry, 1997
- HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5Nature, 1996
- Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharideBrain Research, 1996
- Pharmacological evidence that nitric oxide can act as an endogenous antipyretic factor in endotoxin-induced fever in rabbitsGeneral Pharmacology: The Vascular System, 1995
- Nitric oxide, a novel neuronal messengerNeuron, 1992
- NG-Monomethyl-l-arginine co-injection attenuates the thermogenic and hyperthermic effects of E2 prostaglandin microinjection into the anterior hypothalamic preoptic area in ratsBrain Research, 1991
- CHANGES IN BODY TEMPERATURE AND OXYGEN CONSUMPTION RATE OF CONSCIOUS MICE PRODUCED BY INTRAHYPOTHALAMIC AND INTRACEREBROVENTRICULAR INJECTIONS OF Δ9‐TETRAHYDROCANNABINOLBritish Journal of Pharmacology, 1982